Peptide Based Metabolic Disorders Therapeutics Market Landscape to 2034: Key Forces Shaping the Next Decade of Growth

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Peptide Based Metabolic Disorders Therapeutics Market Size By 2025?
The market size of peptide-based metabolic disorder treatments has been rapidly expanding in recent years. It's projected to swell from $29.89 billion in 2024 to $34.4 billion in 2025 with a compound annual growth rate (CAGR) of 15.1%. The growth witnessed in the past period can be ascribed to factors such as rising healthcare spending, the surge in metabolic disorder cases, advances in peptide synthesis techniques, an aging population, expansion of the biopharmaceutical sector, regulatory green lights for novel therapies, and heightened awareness of personalized medicines.

How Big Is the Peptide Based Metabolic Disorders Therapeutics Market Size Expected to Grow by 2029?
It is projected that the peptide-based metabolic disorders therapeutics market will experience significant expansion in the coming years, potentially reaching $59.85 billion in 2029 with a compound annual growth rate (CAGR) of 14.8%. This growth in the predicted timeframe can be accredited to the emergence of new peptide analogs, increased funding in metabolic disorder research and development initiatives, adoption of precision medical practices, and the surge of emerging markets. Additional contributing factors include partnerships in drug development, advancements in delivery methods, and a focus on patient-centered treatments. Forecasts for the market are also influenced by a variety of trends, including the use of artificial intelligence (AI) in drug discovery, the escalation of personalized treatments, the application of CRISPR/Cas9 for gene therapies, the inclusion of wearable devices in patient monitoring, the formulation of oral peptides, the inclusion of digital therapies in disease management, and the utilization of biobanking for tailored treatments.

View the full report here:
https://www.thebusinessresearchcompany.com/report/peptide-based-metabolic-disorders-therapeutics-global-market-report

Which Key Market Drivers Powering Peptide Based Metabolic Disorders Therapeutics Market Expansion and Growth?
The increasing instances of obesity are anticipated to fuel the expansion of the peptide-based metabolic disorders therapeutic market. Obesity, defined by an extreme accumulation of body fat that poses a risk to health, is on the rise due to factors such as sedentary lifestyles, poor dietary habits, genetic factors, and environmental conditions encouraging calorie-dense diets and lack of physical activity. Therapies for peptide-based metabolic disorders aim to manage obesity and similar conditions by using peptides to regulate metabolic activity, enhance insulin sensitivity, and curb appetite, consequently improving patient health resolutions and diminishing the long-term health hazards linked to these chronic disorders. For example, The British Diabetic Association, widely recognized as a UK-based healthcare and research charity, reported in April 2024 that 4.4 million people in the UK are living with diabetes, and another estimated 1.2 million people may have undiagnosed type 2 diabetes. The registration data for 2022-23 indicates a rise of 167,822 from 2021-22. Therefore, the growing instance of obesity is a major factor propelling the peptide-based metabolic disorder therapeutics market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16764&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Peptide Based Metabolic Disorders Therapeutics Market?
Top companies within the peptide-based metabolic disorder therapeutics market are focusing their efforts on creating innovative peptides for treatment to satisfy unmet medical requirements and broaden the scope of patient treatment. Biosimilars, specifically those for anti-diabetics, are therapeutic medicines modelled after existing peptide-based therapies used for diabetes. They come with similar safety and efficacy standards and could potentially reduce treatment expenses due to the competitive way they are priced. For example, Glenmark Pharmaceuticals Ltd., a pharmaceutical firm based in India, introduced Lirafit, a biosimilar of the famous anti-diabetic medication Liraglutide, in India in January 2024. Lirafit is part of the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) class of medications. This group of medication reproduces the effect of the naturally present GLP-1 hormone, which is essential in controlling blood sugar levels. Lirafit underwent clinical trials to show its effectivity in reducing glycemic parameters and promoting weight loss, while also improving cardiovascular safety. These benefits are crucial in managing diabetes and related conditions like obesity and cardiovascular diseases.

What Are the Emerging Segments in the Peptide Based Metabolic Disorders Therapeutics Market?
The peptide based metabolic disorders therapeutics market covered in this report is segmented -

1) By Drug Type: Liraglutide, Exenatide, Other Drug Type
2) By Application: Lysosomal Storage Diseases, Diabetes, Obesity, Hypercholesterolemia, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Liraglutide: Brand: Saxenda, Brand: Victoza, Generic Liraglutide, Liraglutide For Type 2 Diabetes, Liraglutide For Obesity
2) By Exenatide: Brand: Byetta, Brand: Bydureon, Exenatide For Type 2 Diabetes, Extended-Release Exenatide, Generic Exenatide
3) By Other Drug Type: Semaglutide, Dulaglutide, Albiglutide, Lixisenatide, GLP-1 Receptor Agonists, Pramlintide, Other Peptide-Based Drugs For Metabolic Disorders

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=16764&type=smp

Who Are the Global Leaders in the Peptide Based Metabolic Disorders Therapeutics Market?
Major companies operating in the peptide based metabolic disorders therapeutics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, Merck And Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Eli Lilly Company, Amgen Inc., Gilead Sciences Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Jazz Pharmaceuticals plc, Ipsen S.A, BioMarin Pharmaceutical Inc., Amarin Corporation plc, PolyPeptide Group

Which are the Top Profitable Regional Markets for the Peptide Based Metabolic Disorders Therapeutics Industry?
North America was the largest region in the peptide based metabolic disorders therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide based metabolic disorders therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16764

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.